The potential anti-amyloidogenic candidate, SPA1413, for Alzheimer's disease
- Authors
- An, Seong Soo A.; Shim, Kyu Hwan; Kang, Shinwoo; Kim, Young Kyo; Subedi, Lalita; Cho, Hyewon; Hong, Seong-Min; Tan, Mario A.; Jeon, Raok; Chang, Keun-A; Kim, Sun Yeou
- Issue Date
- Mar-2022
- Publisher
- WILEY
- Keywords
- Alzheimer' s disease; drug discovery; isoflavone; neuroinflammation; oligomerization
- Citation
- BRITISH JOURNAL OF PHARMACOLOGY, v.179, no.5, pp.1033 - 1048
- Journal Title
- BRITISH JOURNAL OF PHARMACOLOGY
- Volume
- 179
- Number
- 5
- Start Page
- 1033
- End Page
- 1048
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83645
- DOI
- 10.1111/bph.15691
- ISSN
- 0007-1188
- Abstract
- Background and Purpose Recently, isoflavone derivatives have been shown to have neuroprotective effects against neurological disorders. For instance, genistein attenuated the neuroinflammation and amyloid-beta accumulation in Alzheimer's disease animal models, suggesting the potential for use to prevent and treat Alzheimer's disease. Experimental Approach Here, 50 compounds, including isoflavone derivatives, were constructed and screened for the inhibitory effects on amyloid-beta(42) fibrilization and oligomerization using the high-throughput screening formats of thioflavin T assay and multimer detection system, respectively. The potential neuroprotective effect of t3-(4-hydroxyphenyl)-2H-chromen-7-ol (SPA1413), also known as dehydroequol, idronoxil or phenoxodiol, was evaluated in cells and in 5xFAD (B6SJL) transgenic mouse, a model of Alzheimer's disease. Key Results SPA1413 had a potent inhibitory action on both amyloid-beta fibrilization and oligomerization. In the cellular assay, SPA1413 prevented amyloid-beta-induced cytotoxicity and reduced neuroinflammation. Remarkably, the oral administration of SPA1413 ameliorated cognitive impairment, decreased amyloid-beta plaques and activated microglia in the brain of 5xFAD (B6SJL) transgenic mouse. Conclusion and Implications Our results strongly support the repurposing of SPA1413, which has already received fast-track status from the US Food and Drug Administration (FDA) for cancer treatment, for the treatment of Alzheimer's disease due to its potent anti-amyloidogenic and anti-neuroinflammatory actions.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 약학대학 > 약학과 > 1. Journal Articles
- 의과대학 > 의예과 > 1. Journal Articles
- 산업·환경대학원 > 산업환경공학과 > 1. Journal Articles
- 바이오나노대학 > 바이오나노학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.